scholarly journals Comparison of SARC-F Score among Gastrointestinal Diseases

2021 ◽  
Vol 10 (18) ◽  
pp. 4099
Author(s):  
Kosuke Ushiro ◽  
Hiroki Nishikawa ◽  
Masahiro Matsui ◽  
Takeshi Ogura ◽  
Toshihisa Takeuchi ◽  
...  
Keyword(s):  
Advanced Cancer ◽  
Gastrointestinal Disease ◽  
Gastrointestinal Diseases ◽  
Pancreatic Disease ◽  
Prognostic Scores ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Primary Origin ◽  
Upper Gastrointestinal ◽  
Significant Factors

SARC-F is a screening tool for sarcopenia. We sought to compare the SARC-F scores of patients with different gastrointestinal diseases (n = 1282 (762 males): upper gastrointestinal disease (UGD, n = 326), lower gastrointestinal disease (LGD, n = 357), biliary and pancreatic disease (BPD, n = 416), and liver disease (LD, n = 183)). Factors associated with SARC-F ≥4 points (highly suspicious of sarcopenia) were also examined. The median age was 71 years. Patients with SARC-F ≥4 points were found in 197 (15.4%). Advanced cancer was found in 339 patients (26.4%). The proportion of SARC-F ≥4 points in groups of UGD, LGD, BPD, and LD were 17.5% (57/326) in UGD, 12.0% (43/357) in LGD, 17.3% (72/416) in BPD, and 13.7% (25/183) in LD, respectively (overall p = 0.1235). In patients with and without advanced cancer, similar tendencies were observed. In the multivariate analysis, age (p < 0.0001), gender (p = 0.0011), serum albumin (p < 0.0001), lymphocyte count (p = 0.0019), C reactive protein (p = 0.0197), and the presence of advanced cancer (p = 0.0424) were significant factors linked to SARC-F ≥4 points. In patients with advanced cancer, SARC-F scores correlated well with their Glasgow prognostic scores. In conclusion, sarcopenia in gastrointestinal diseases may be affected not by disease type (i.e., the primary origin of the disease) but by aging, nutritional condition, inflammatory condition, and cancer burden.

scholarly journals Predictors and trajectory of performance status in patients with advanced cancer: A secondary data analysis of the international European Palliative Care Cancer Symptom study

2018 ◽  
Vol 33 (2) ◽  
pp. 206-212 ◽  
Author(s):  
Jason W Boland ◽  
Victoria Allgar ◽  
Elaine G Boland ◽  
Stein Kaasa ◽  
Marianne J Hjermstad ◽  
...  
Keyword(s):  
Palliative Care ◽  
Data Analysis ◽  
Physical Function ◽  
Advanced Cancer ◽  
Independent Living ◽  
Performance Status ◽  
Secondary Data ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Explanatory Factors

Background: Performance status, a predictor of cancer survival, and ability to maintain independent living deteriorate in advanced disease. Understanding predictors of performance status trajectory could help identify those at risk of functional deterioration, target support for independent living and reduce service costs. The relationship between symptoms, analgesics and performance status is poorly delineated. Aim: The aim of this study is to determine whether demographics, analgesics, disease characteristics, quality-of-life domains and C-reactive protein predict the trajectory of Karnofsky Performance Status (KPS) in patients with advanced cancer. Design: The study design is the secondary data analysis of the international prospective, longitudinal European Palliative Care Cancer Symptom study (ClinicalTrials.gov: NCT01362816). A multivariable regression model was built for KPS area under the curve per day (AUC). Setting and participants: This included adults with advanced, incurable cancer receiving palliative care, without severe cognitive impairment and who were not imminently dying ( n = 1739). Results: The mean daily KPS AUC ( n = 1052) was 41.1 (standard deviation = 14.1). Opioids ( p < 0.001), co-analgesics ( p = 0.023), poorer physical functioning ( p < 0.001) and appetite loss ( p = 0.009) at baseline were explanatory factors for lower KPS AUC. A subgroup analysis of participants with C-reactive protein data ( n = 240) showed that only C-reactive protein ( p = 0.040) and physical function ( p < 0.001) were associated with lower KPS AUC. Conclusion: This study is novel in determining explanatory factors for subsequent functional trajectories in an international dataset and identifying systemic inflammation as a candidate therapeutic target to improve functional performance. The effect of interventions targeting physical function, appetite and inflammation, such as those used for cachexia management, on maintaining functional status in patients with advanced cancer needs to be investigated.

scholarly journals Endoscopic Methods for the Treatment of Nonvariceal Upper Gastrointestinal Hemorrhage

1989 ◽  
Vol 3 (2) ◽  
pp. 72-76 ◽  
Author(s):  
Z.W. Li ◽  
F. Urrutia ◽  
R. Wensel ◽  
A.B.R. Thomson
Keyword(s):  
Gastrointestinal Disease ◽  
Gastrointestinal Diseases ◽  
Ulcer Bleeding ◽  
Therapeutic Modalities ◽  
Visible Vessel ◽  
Hemostatic Therapy ◽  
Poor Outcomes ◽  
Bleeding Ulcers ◽  
Endoscopic Methods ◽  
Upper Gastrointestinal

In the l970s, diagnostic fibreoptic endoscopy became part of the standard practice for evaluation of gastrointestinal disease. In the 1980s, therapeutic fibreoptic endoscopy is emerging as standard therapy for many gastrointestinal diseases. As the already sophisticated technology continues to blossom, it promises to become even more a part of the management of an increasing number of gastroenterological problems. Endoscopy can provide both a specific diagnosis as well as an identification of the high risk subgroup of patients with either active bleeding, or a non bleeding visible vessel that might benefit from endoscopic treatment. At endoscopy, patients with active ulcer bleeding have either arterial spurting, oozing or oozing beneath an overlying clot. These have poor outcomes: for example, when a non bleeding visible vessel is identified, the chances for rebleeding are approximately 50% during the period of that hospitalization . With an overlying clot without oozing, where dark spots are noted, there is less than a 10% chance of rebleeding. There are certain limitations for endoscopic hemostatic therapy and there are a few bleeding ulcers with an artery too large to expect endoscopic success. The kind of treatment chosen will be dictated by the availability of the therapeutic modalities and the skill of the surgeon.

scholarly journals Pilot study on serum C-reactive protein in pet rabbits: clinical usefulness

2019 ◽  
Vol 6 (1) ◽  
pp. e000272
Author(s):  
Eiji Oohashi ◽  
Yuki Kimura ◽  
Kotaro Matsumoto
Keyword(s):  
Clinical Practice ◽  
Mortality Rate ◽  
Gastrointestinal Disease ◽  
Healthy Controls ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Dermatological Disease ◽  
Significant Difference ◽  
Before And After ◽  
Wbc Count

ObjectivesThe present study was performed to evaluate the usefulness of serum C-reactive protein (CRP) as an acute phase reactive protein in pet rabbits in clinical practice.MethodsThe CRP level using a rabbit CRP ELISA and white blood cell (WBC) count in pet rabbits (30 healthy controls and 62 with various diseases) were measured in the clinical practice setting. The CRP level and WBC count were measured before and after ovariohysterectomy of a healthy rabbit and a rabbit with uterine adenocarcinoma. The association between the CRP level and mortality in rabbits with various diseases was assessed.ResultsThe CRP level in healthy controls was 0.52±0.82 mg/dl (mean±SD). No age and sex-related differences in neither the CRP level nor WBC count were observed in the healthy control rabbits. The CRP levels in rabbits with gastrointestinal disease (n=22, 11.74±22.89 mg/dl), reproductive and urinary system disease (n=20, 21.19±49.68 mg/dl), dental disease (n=6, 4.87±5.47 mg/dl) and musculoskeletal disease (n=4, 85.66±107.28 mg/dl) were significantly higher than those in healthy controls. The CRP levels in rabbits with neurological disease (n=7, 2.55±1.79 mg/dl) and dermatological disease (n=3, 8.84±7.71 mg/dl) were higher than those in healthy controls, but no significant difference was observed. The WBC counts were not significantly different between rabbits with diseases and healthy controls. Serum samples were collected from two rabbits before and after ovariohysterectomy. In both rabbits, the CRP peaked on postoperative day 1, but no obvious WBC peak was observed. The mortality rate increased as the CRP level increased; the mortality rate was significantly higher in rabbits with a CRP level of ≥100 mg/dl than of <10 mg/dl.ConclusionsThis study indicates that the serum CRP level is useful to determine the disease status, monitor the treatment course and evaluate the prognosis in pet rabbits in clinical practice.

A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 3025-3025 ◽  
Author(s):  
S. J. Clarke ◽  
J. T. Smith ◽  
C. Gebbie ◽  
C. Sweeney ◽  
N. Olszewski
Keyword(s):  
Advanced Cancer ◽  
Vital Signs ◽  
Primary Objective ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Hand Grip ◽  
Efficacy Assessment ◽  
Infusion Reactions ◽  
Grade 3 ◽  
Dose Escalating

3025 Background: ALD518 is a humanized anti-IL-6 antibody being developed for the treatment of cancer cachexia and fatigue. The primary objective of the study was to determine the safety of ALD518. Methods: 9 patients (pts) with advanced cancer, ECOG 0–2, and C-reactive protein (CRP) >10mg/L were enrolled. Pts were assigned to 1 of 3 dose-escalating cohorts (n=3/cohort). ALD518 was given as a single i.v. infusion of 80mg, 160mg, or 320mg. Pts were followed up for 12 weeks. Data included lab safety tests (LSTs), vital signs, ECGs, adverse events, hand grip strength (HGS), FACIT-F, PK and C-reactive protein (CRP). Results: 9 pts were evaluable for dose limiting toxicity (DLT) assessment at week 4 and 5/9 pts completed all visits. Of the 4 pts who failed to complete every visit; 3 were withdrawn due to progressive disease and 1 to be treated with chemotherapy. There were no DLTs or infusion reactions. There were 4 SAEs: 3 disease progressions and 1 sepsis secondary to a blocked biliary stent. There were no grade 3/4 toxicities. Changes in LSTs, CRP, HGS and FACIT-F fatigue subscale (pooled ITT analysis) are shown (Table). Conclusions: ALD518 given to pts with advanced cancer was safe and well tolerated. ALD518 reversed fatigue, increased hemoglobin and albumin, and there was a trend to increased HGS. There was a mild decrease in platelet count that remained stable throughout the study. [Table: see text] [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document